SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
New Antibody Formats
- 1st Edition, Volume 369 - June 20, 2022
- Editors: Fernando Aranda Vega, Pedro Berraondo, Lorenzo Galluzzi
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 4 0 2 - 6
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 4 1 0 - 1
New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting intere… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNew Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting interesting chapters on a variety of important topics, including Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the International Review of Cell and Molecular Biology serials
- Updated release includes the latest information on New Antibody Formats
Academics, researchers and educators
- Cover image
- Title Page
- Table of Contents
- Copyright
- Contributors
- Chapter One: Current innovative engineered antibodies
- Abstract
- 1: Introduction
- 2: Historical overview of antibody engineering
- 3: Bispecific antibodies
- 4: Nanobodies
- 5: Intrabodies
- 6: Fine-tuning Fc-dependent effector functions
- 7: Antibody–drug conjugates
- 8: Engineered antibody fusion proteins
- 9: CAR-T and CAR-NK cells
- 10: Conclusions
- Acknowledgments
- References
- Chapter Two: Opportunities and challenges of bi-specific antibodies
- Abstract
- 1: Introduction
- 2: Cis- versus trans-targeting bispecific antibodies
- 3: Technical challenges in the design and production of bispecific antibodies
- 4: Examples of BsAbs approved for clinical application
- 5: Further opportunities for bispecific antibodies on the example of regulatory T-cells
- 6: Current bi-specific antibodies targeting regulatory T-cells
- 7: Concluding remarks
- References
- Chapter Three: Applications of trimerbodies in cancer immunotherapy
- Abstract
- 1: Introduction
- 2: Next-generation antibodies
- 3: The trimerbody concept and evolution
- 4: Trimerbodies in cancer immunotherapy
- 5: Trimerbodies in cancer diagnosis
- 6: Conclusions and future prospects
- References
- Chapter Four: Anticalin®-based therapeutics: Expanding new frontiers in drug development
- Abstract
- 1: Introduction
- 2: Anticalin protein technology
- 3: Format opportunities for Anticalin proteins
- 4: Plasma half-life engineering of Anticalin proteins
- 5: Anticalin protein based multispecifics for potential treatment of infectious diseases
- 6: Antibody-Anticalin fusion formats for cancer immunotherapy
- 7: Armoring cancer immunotherapies with Anticalin protein-based payloads
- 8: Inhalable Anticalin proteins for local lung delivery
- 9: Concluding remarks
- References
- Chapter Five: Overcoming the limitations of cytokines to improve cancer therapy
- Abstract
- 1: Introduction
- 2: Strategies to modulate the activity
- 3: Strategies to increase the half-life
- 4: Strategies to target the tumor microenvironment
- 5: In vivo production of cytokines
- 6: Conclusions
- Acknowledgments
- References
- Chapter Six: Emerging applications of nanobodies in cancer therapy
- Abstract
- 1: Introduction
- 2: Nanobodies: Small antigen-binding proteins with a big impact on conventional cancer therapies
- 3: Nanobodies: Emerging applications in cancer immunotherapy
- 4: Conclusion
- References
- No. of pages: 212
- Language: English
- Edition: 1
- Volume: 369
- Published: June 20, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323994026
- eBook ISBN: 9780323994101
FA
Fernando Aranda Vega
Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.
Affiliations and expertise
Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, SpainPB
Pedro Berraondo
Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.
Affiliations and expertise
CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, SpainLG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USARead New Antibody Formats on ScienceDirect